| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Cefpiramide is a third-generation cephalosporin antibiotic. |
| Indication |
For treatment of severe infections caused by susceptible bacteria such as P. aeruginosa. |
| Pharmacology |
Cefpiramide is a cephalosporin active against Pseudomonas aeruginosa. It has a broad spectrum of antibacterial activity. Cefpiramide works by inhibiting bacterial cell wall biosynthesis. The plasma half-lives of cefpiramide in rabbits, dogs, and rhesus monkeys were much longer than those of cefoperazone and cefazolin. |
| Toxicity |
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Absorption |
Rapidly absorbed following intramuscular injection. |
| Half Life |
4.44 hours |
| References |
| • |
Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M: In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. J Infect Chemother. 2000 Jun;6(2):81-5.
[Pubmed]
|
| • |
Iakovlev VP, Vishnevskii VA, Khlebnikov EP, Khadin IM, Plavlova MV, Elagina LV, Izotova GN: [Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery] Antibiot Khimioter. 1995 Sep;40(9):30-4.
[Pubmed]
|
| • |
Sampi K, Hattori M: [Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study] Gan To Kagaku Ryoho. 1992 Aug;19(9):1315-20.
[Pubmed]
|
|
| External Links |
|
|